Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk today announced the headline results from SWITCH 1, the second of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, comparing the safety and efficacy of Tresiba ® (insulin degludec) and Lantus ® (insulin glargine U100). The overall purpose of the trial was to compare the hypoglycaemia occurrence in people with type 1 diabetes treated with Tresiba ® or insulin glargine.
In the trial, 501 people with type 1 diabetes were randomised to cross-over treatment with Tresiba ® and insulin glargine U100 in combination with insulin aspart. The timing of the daily injections of both Tresiba ® and insulin glargine was randomised equally to take place either in the morning or evening. The primary end-point of the trial was the number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemia episodes during the maintenance period (ie after 16 weeks of treatment) in each treatment period.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=154179#.VsxCfvmLTIU
In the trial, 501 people with type 1 diabetes were randomised to cross-over treatment with Tresiba ® and insulin glargine U100 in combination with insulin aspart. The timing of the daily injections of both Tresiba ® and insulin glargine was randomised equally to take place either in the morning or evening. The primary end-point of the trial was the number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemia episodes during the maintenance period (ie after 16 weeks of treatment) in each treatment period.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=154179#.VsxCfvmLTIU